赛诺菲安万特(SNY)

盘后45.020.000.00%17:33 EDT

45.02+0.64+1.44%

社区社区
资讯资讯
资料资料
公告公告

- 最新
- 推荐
- 异动解读｜赛诺菲安万特盘中上涨4.59%，全球首创新药获FDA优先审评
  行情直击 · 06-04 22:06
  异动解读｜赛诺菲安万特盘中上涨4.59%，全球首创新药获FDA优先审评
- 异动解读｜赛诺菲安万特盘前上涨3.09%，全球首创新药获FDA优先审评
  行情直击 · 06-04 17:05
  异动解读｜赛诺菲安万特盘前上涨3.09%，全球首创新药获FDA优先审评
- 赛诺菲(SNY.US)全球首创新药申报上市
  智通财经 · 05-28
  赛诺菲(SNY.US)全球首创新药申报上市
- 跨国药企开门红巨头领跑减重赛道 “王牌”产品成增长胜负手
  21世纪经济报道 · 05-08
  跨国药企开门红巨头领跑减重赛道 “王牌”产品成增长胜负手
- 跨国药企业绩大爆发，集体加仓中国
  21世纪经济报道 · 05-07
  跨国药企业绩大爆发，集体加仓中国
- 靠Dupixent还能“躺赢”多久？赛诺菲(SNY.US)业绩报喜难掩研发焦虑股价承压静待新帅破局
  智通财经 · 04-23
  靠Dupixent还能“躺赢”多久？赛诺菲(SNY.US)业绩报喜难掩研发焦虑股价承压静待新帅破局
- 辉瑞、赛诺菲押注！AI制药估值10亿美元，22款药物进入临床！
  智药局 · 04-16
  辉瑞、赛诺菲押注！AI制药估值10亿美元，22款药物进入临床！
- 财报前瞻｜赛诺菲安万特本季度营收预计增10.21%，机构观点偏正面
  财报Agent · 04-16
  财报前瞻｜赛诺菲安万特本季度营收预计增10.21%，机构观点偏正面
- 还没进临床，就融了10亿：华人创立眼科biotech为何屡获巨头押注？
  药融圈 · 03-12
  还没进临床，就融了10亿：华人创立眼科biotech为何屡获巨头押注？
- 赛诺菲换帅，任命默克KGaA首席执行官为下一任CEO
  环球市场播报 · 02-13
  赛诺菲换帅，任命默克KGaA首席执行官为下一任CEO
- 65岁西班牙人成为赛诺菲史上首位女CEO，为何股价下跌
  第一财经 · 02-13
  65岁西班牙人成为赛诺菲史上首位女CEO，为何股价下跌
- 研发失速叠加特朗普变量赛诺菲(SNY.US)新CEO加里霍面临双重挑战
  智通财经 · 02-13
  研发失速叠加特朗普变量赛诺菲(SNY.US)新CEO加里霍面临双重挑战
- 赛诺菲(SNY.US)突发换帅：研发“哑火”成“催命符”，默沙东高管火线接手
  智通财经 · 02-12
  赛诺菲(SNY.US)突发换帅：研发“哑火”成“催命符”，默沙东高管火线接手
- 明星药物Dupixent销售额再创新高！赛诺菲(SNY.US)Q4盈利超预期
  智通财经 · 01-29
  明星药物Dupixent销售额再创新高！赛诺菲(SNY.US)Q4盈利超预期
- 财报前瞻｜赛诺菲安万特本季度营收预计增17.09%，机构观点偏正面
  财报Agent · 01-22
  财报前瞻｜赛诺菲安万特本季度营收预计增17.09%，机构观点偏正面
- 独家：FDA推迟赛诺菲糖尿病药物Tzield与Disc Medicine血液疾病药物审评时间表 - 文件披露
  美股速递 · 01-15
  独家：FDA推迟赛诺菲糖尿病药物Tzield与Disc Medicine血液疾病药物审评时间表 - 文件披露
- Anthropic与赛诺菲(SNY)、诺和诺德(NVO)等生物制药公司合作进军医疗保健人工智能领域
  金吾财讯 · 01-14
  Anthropic与赛诺菲(SNY)、诺和诺德(NVO)等生物制药公司合作进军医疗保健人工智能领域
- 赛诺菲安万特(SNY)盘前升0.5% 普乐司兰钠注射液在华获批
  金吾财讯 · 01-06
  赛诺菲安万特(SNY)盘前升0.5% 普乐司兰钠注射液在华获批
- 12月24日美股盘前要闻
  钛媒体快报 · 2025-12-24
  12月24日美股盘前要闻
- 赛诺菲以每股15.50美元的现金价格收购Dynavax所有流通股
  老虎资讯综合 · 2025-12-24
  赛诺菲以每股15.50美元的现金价格收购Dynavax所有流通股
公司概况
公司名称
赛诺菲安万特
所属市场
NASDAQ
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
http://www.sanofi.com
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
Sanofi于1994年根据法国法律注册成立。该公司是一家全球领先的医疗保健公司，专注于患者需求并从事治疗解决方案的研究、开发、制造和营销。该公司的活动围绕以下类别组织：DUPIXENT、神经病学&免疫学、罕见病、肿瘤学、罕见血液病、普药核心资产和非核心资产、疫苗、CHC。
- 05-06
  超过5%披露
  Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
  Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
- 04-10
  超过5%披露
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 02-17
  员工持股计划
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 02-17
  年度报告
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 02-05
  员工持股计划
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
- 2025-10-28
  [补充]招股说明书
  Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
  Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
- 2025-10-28
  [补充]招股说明书
  Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
  Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
- 2025-10-28
  [补充]招股说明书
  Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
  Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
- 2025-10-28
  [补充]招股说明书
  Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
  Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
- 2025-10-28
  [补充]招股说明书
  Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
  Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
- 2025-06-27
  员工持股计划
  Form 11-K - Annual report of employee stock purchase, savings and similar plans
  Form 11-K - Annual report of employee stock purchase, savings and similar plans
- 2025-06-27
  员工持股计划
  Form 11-K - Annual report of employee stock purchase, savings and similar plans
  Form 11-K - Annual report of employee stock purchase, savings and similar plans
- 2025-03-27
  员工持股计划
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 2025-03-21
  员工持股计划
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
- 2025-02-13
  年度报告
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

分时
5日
日
周
月

数据加载中...

最高

45.24

今开

45.00

量比

1.10

最低

44.83

昨收

44.38

换手率

0.12%

赛诺菲安万特(SNY)

公司概况

热议股票